Honorary Professor

Janet Hardy

Email: 

Availability

Honorary Professor Janet Hardy is:
Available for supervision

Fields of research

Health Sciences Oncology and carcinogenesis Pharmacology and pharmaceutical sciences

Qualifications

  • Royal Australasian College of Physicians, Royal Australasian College of Physicians

Search Professor Janet Hardy’s works on UQ eSpace

257 works between 1987 and 2025
All (257) Journal Article (203) Book Chapter (26) Conference Publication (26) Book (1) Other Outputs (1)

221 - 240 of 257 works

1998

Journal Article

A survey of transdermal fentanyl use in a major cancer center

Hardy, JR (1998). A survey of transdermal fentanyl use in a major cancer center. Journal of Pain and Symptom Management, 15 (4), 213-214.

A survey of transdermal fentanyl use in a major cancer center

1998

Journal Article

The use of the Edmonton Symptom Assessment Scale (ESAS) within a palliative care unit in the UK

Rees, E, Hardy, J, Ling, J, Broadley, K and A'Hern, R (1998). The use of the Edmonton Symptom Assessment Scale (ESAS) within a palliative care unit in the UK. Palliative Medicine, 12 (2), 75-82. doi: 10.1191/026921698674135173

The use of the Edmonton Symptom Assessment Scale (ESAS) within a palliative care unit in the UK

1997

Journal Article

Placebo-controlled trials in palliative care: the argument for

Hardy, JR (1997). Placebo-controlled trials in palliative care: the argument for. Palliative Medicine, 11 (5), 415-418. doi: 10.1177/026921639701100514

Placebo-controlled trials in palliative care: the argument for

1997

Journal Article

Palliative medicine in cancer

Stone, Patrick and Hardy, Janet (1997). Palliative medicine in cancer. The Lancet, 350 (9073), 296. doi: 10.1016/s0140-6736(05)62270-2

Palliative medicine in cancer

1997

Journal Article

Can transdermal fentanyl cause diarrhea?

Hardy, Janet R. (1997). Can transdermal fentanyl cause diarrhea?. Journal of Pain and Symptom Management, 13 (4), 188-189. doi: 10.1016/s0885-3924(97)00037-7

Can transdermal fentanyl cause diarrhea?

1995

Journal Article

Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD)

Ling, P. J., Ahern, R. P. and Hardy, J. R. (1995). Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). British Journal of Cancer, 72 (1), 206-209. doi: 10.1038/bjc.1995.304

Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD)

1995

Journal Article

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer

Ellis, P. A., Smith, I. E., Hardy, J. R., Nicolson, M. C., Talbot, D. C., Ashley, S. E. and Priest, K. (1995). Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. British Journal of Cancer, 71 (2), 366-370. doi: 10.1038/bjc.1995.74

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer

1995

Journal Article

Subcutaneous Ketorolac

Duncan, AR, Hardy, JR and Davis, CL (1995). Subcutaneous Ketorolac. Palliative Medicine, 9 (1), 77-78. doi: 10.1177/026921639500900111

Subcutaneous Ketorolac

1994

Journal Article

Current issues in cancer palliative care

Davis, C. L. and Hardy, J. R. (1994). Current issues in cancer palliative care. BMJ, 308 (6940), 1359-1362. doi: 10.1136/bmj.308.6940.1359

Current issues in cancer palliative care

1994

Journal Article

An audit of morphine prescribing in a specialist cancer hospital

Turner, Rose, Clark, Judith, Root, Timothy and Hardy, Janet (1994). An audit of morphine prescribing in a specialist cancer hospital. Palliative Medicine, 8 (1), 5-10. doi: 10.1177/026921639400800102

An audit of morphine prescribing in a specialist cancer hospital

1994

Journal Article

Prediction of Survival in a Hospital-Based Continuing Care Unit

Hardy, JR, Turner, R, Saunders, M and Ahern, R (1994). Prediction of Survival in a Hospital-Based Continuing Care Unit. European Journal of Cancer, 30A (3), 284-288. doi: 10.1016/0959-8049(94)90242-9

Prediction of Survival in a Hospital-Based Continuing Care Unit

1992

Journal Article

A Phase-Ii Study of Sulofenur, a Novel Sulfonylurea, in Recurrent Epithelial Ovarian-Cancer

Obrien, Mer, Hardy, J, Tan, S, Walling, J, Peters, B, Hatty, S and Wiltshaw, E (1992). A Phase-Ii Study of Sulofenur, a Novel Sulfonylurea, in Recurrent Epithelial Ovarian-Cancer. Cancer Chemotherapy and Pharmacology, 30 (3), 245-248. doi: 10.1007/BF00686324

A Phase-Ii Study of Sulofenur, a Novel Sulfonylurea, in Recurrent Epithelial Ovarian-Cancer

1991

Journal Article

Phase II Study of the Amsacrine Analog Ci-921 (nsc 343499) in Non-Small-Cell Lung-Cancer

Harvey, VJ, Hardy, JR, Smith, S, Grove, W and Baguley, BC (1991). Phase II Study of the Amsacrine Analog Ci-921 (nsc 343499) in Non-Small-Cell Lung-Cancer. European Journal of Cancer, 27 (12), 1617-1620. doi: 10.1016/0277-5379(91)90427-F

Phase II Study of the Amsacrine Analog Ci-921 (nsc 343499) in Non-Small-Cell Lung-Cancer

1991

Journal Article

Hypoprothrombinemia From Coadministration of Sulofenur (ly-186641) and Warfarin - Report of 3 Cases

Fossella, FV, Lippman, SM, Seitz, DE, Alberts, DS, Taylor, CW, Wiltshaw, E, Hardy, J, Obrien, M, Haynes, TR and Wolen, RL (1991). Hypoprothrombinemia From Coadministration of Sulofenur (ly-186641) and Warfarin - Report of 3 Cases. Investigational New Drugs, 9 (4), 357-359.

Hypoprothrombinemia From Coadministration of Sulofenur (ly-186641) and Warfarin - Report of 3 Cases

1991

Journal Article

Lymphedema - Prevention Rather Than Cure

Hardy, JR (1991). Lymphedema - Prevention Rather Than Cure. Annals of Oncology, 2 (8), 532-533. doi: 10.1093/oxfordjournals.annonc.a058015

Lymphedema - Prevention Rather Than Cure

1991

Journal Article

A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer

Powles, T. J., Jones, A. L., Judson, I. R., Hardy, J. R. and Ashley, S. E. (1991). A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. British Journal of Cancer, 64 (2), 406-410. doi: 10.1038/bjc.1991.318

A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer

1991

Journal Article

The Pharmacokinetics of Oral Lonidamine in Breast and Lung-Cancer Patients

Newell, DR, Mansi, J, Hardy, J, Button, D, Jenns, K, Smith, IE, Picollo, R and Catanese, B (1991). The Pharmacokinetics of Oral Lonidamine in Breast and Lung-Cancer Patients. Seminars in Oncology, 18 (2), 11-17.

The Pharmacokinetics of Oral Lonidamine in Breast and Lung-Cancer Patients

1991

Journal Article

Cisplatin and Carboplatin in Combination for the Treatment of Stage-Iv Ovarian-Carcinoma

Hardy, JR, Wiltshaw, E, Blake, PR, Harper, P, Slevin, M, Perren, TJ and Tan, S (1991). Cisplatin and Carboplatin in Combination for the Treatment of Stage-Iv Ovarian-Carcinoma. Annals of Oncology, 2 (2), 131-136. doi: 10.1093/oxfordjournals.annonc.a057876

Cisplatin and Carboplatin in Combination for the Treatment of Stage-Iv Ovarian-Carcinoma

1991

Journal Article

Clinical-Study and Pharmacokinetics of Lonidamine in Advanced Non-Small Cell Lung-Cancer

Jones, AL, Hardy, JR, Newell, DR and Smith, IE (1991). Clinical-Study and Pharmacokinetics of Lonidamine in Advanced Non-Small Cell Lung-Cancer. European Journal of Cancer, 27 (4), 519-519. doi: 10.1016/0277-5379(91)90403-Z

Clinical-Study and Pharmacokinetics of Lonidamine in Advanced Non-Small Cell Lung-Cancer

1990

Conference Publication

NEED NEPHROTOXICITY LIMIT DOSE INTENSITY STRATEGIES IN OVARIAN-CANCER

HARDY, J, TAN, S, FRYATT, and WILTSHAW, E (1990). NEED NEPHROTOXICITY LIMIT DOSE INTENSITY STRATEGIES IN OVARIAN-CANCER. BASINGSTOKE: STOCKTON PRESS.

NEED NEPHROTOXICITY LIMIT DOSE INTENSITY STRATEGIES IN OVARIAN-CANCER

Current funding

  • 2021 - 2026
    Medicinal Cannabis (MedCan 3) - randomised, multicentre, double blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer
    NHMRC MRFF EPCDR Medicinal Cannabis
    Open grant

Past funding

  • 2018 - 2023
    Medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer
    NHMRC MRFF - Lifting Clinical Trials Registries Capacity
    Open grant
  • 2017 - 2020
    Talking about death: A study into palliative care communication
    Mater Misericordiae Ltd
    Open grant
  • 2010 - 2016
    A randomised controlled trial of aetiology based antiemetic guidelines for reducing nausea in advanced cancer patients (NHMRC Project Grant administered by QUT)
    Queensland University of Technology
    Open grant
  • 2010 - 2012
    n-of-1 trials of pilocarpine vs placebo for dry mouth in palliative care patients
    Cancer Council Queensland
    Open grant
  • 2009 - 2012
    Using n-of 1 trials to determine the effectiveness of paracetamol in advanced cancer patients on opioids
    NHMRC Palliative Care Research Program
    Open grant
  • 2008 - 2012
    Using single patient trials to determine the effectiveness of psychostimulants in end stage fatigue in cancer patients.
    NHMRC Palliative Care Research Program
    Open grant

Availability

Honorary Professor Janet Hardy is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Enquiries

For media enquiries about Honorary Professor Janet Hardy's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au